FindTrial
Sign In

A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221371
Enrollment
Unknown
Registered
2011-01-28
Start date
2011-01-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

investigational material(s) Generic name etc : LY2140023 INN of investigational material : Therapeutic category code : 117 Psychotropic agents Dosage and Administration for Investigational material :

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Inclusion Criteria] -Must have met all entry criteria for, and have completed, an acute, placebo-controlled clinical trial of LY2140023 (such as Study H8Y-MC-HBBM, or other acute, placebo-controlled LY2140023 studies if allowed by the protocols for those studies). -Female patients of childbearing potential must agree to use a single, effective, medically acceptable method of birth control. -Patients must be considered reliable and have a level of understanding sufficient to perform all tests and examinations required by the protocol. -Patients must be able to understand the nature of the study and have given their own informed consent.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026